Jones Financial Companies Lllp Raises Stock Position in Organon & Co. (NYSE:OGN)

Jones Financial Companies Lllp raised its stake in Organon & Co. (NYSE:OGN) by 1,795.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,550 shares of the company’s stock after buying an additional 4,310 shares during the period. Jones Financial Companies Lllp’s holdings in Organon & Co. were worth $68,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. increased its stake in shares of Organon & Co. by 43.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company’s stock worth $385,000 after purchasing an additional 6,096 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Organon & Co. by 127.3% during the 3rd quarter. Victory Capital Management Inc. now owns 183,298 shares of the company’s stock worth $3,506,000 after purchasing an additional 102,663 shares in the last quarter. KBC Group NV increased its stake in shares of Organon & Co. by 19.5% during the 3rd quarter. KBC Group NV now owns 7,744 shares of the company’s stock worth $148,000 after purchasing an additional 1,263 shares in the last quarter. Natixis Advisors LLC increased its stake in shares of Organon & Co. by 7.9% during the 3rd quarter. Natixis Advisors LLC now owns 48,215 shares of the company’s stock worth $922,000 after purchasing an additional 3,520 shares in the last quarter. Finally, Aljian Capital Management LLC purchased a new position in shares of Organon & Co. during the 3rd quarter worth approximately $196,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OGN has been the subject of a number of recent research reports. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. Finally, Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Stock Performance

Shares of OGN stock opened at $15.63 on Tuesday. The company’s fifty day simple moving average is $15.46 and its 200-day simple moving average is $16.60. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market cap of $4.03 billion, a PE ratio of 4.69, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. As a group, equities research analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.17%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.